TALEN

TALEN1-eng

ID
ZDB-TALEN-170530-1
Name
TALEN1-eng
Previous Names
None
Target
Target Sequence 1
5' - TGCTGTGTTTGCTTCT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Target Sequence 2
5' - TGGAGCTCTTACCTGA - 3'
ZFIN BLAST NCBI BLAST Ensembl
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
mu130 eng
mu131 eng
mu132 eng
Expression
Gene expression in Wild Types + TALEN1-eng
No data available
Phenotype
Phenotype resulting from TALEN1-eng
No data available
Phenotype of all Fish created by or utilizing TALEN1-eng
Phenotype Fish Conditions Figures
regenerating fin blood circulation process quality, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
posterior cardinal vein blood cell increased velocity, abnormal engmu130/mu130 standard conditions Fig. 4 from Sugden et al., 2017
trunk vasculature eng expression decreased amount, abnormal engmu130/mu130 standard conditions Fig. S2 from Sugden et al., 2017
intersegmental vein nucleate erythrocyte absent, abnormal engmu130/mu130 standard conditions Fig. 2 from Sugden et al., 2017
dorsal aorta dilated, abnormal engmu130/mu130 standard conditions Fig. 2,  Fig. S4 from Sugden et al., 2017
regenerating fin vein increased area, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
artery endothelial cell decreased mass density, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
brain blood vessel dilated, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
blood vessel increased diameter, abnormal engmu130/mu130 standard conditions Fig. 3 from Sugden et al., 2017
posterior cardinal vein klf2a expression increased amount, abnormal engmu130/mu130 standard conditions Fig. 5 from Sugden et al., 2017
dorsal aorta blood cell increased velocity, abnormal engmu130/mu130 standard conditions Fig. 4 from Sugden et al., 2017
whole organism decreased size, abnormal engmu130/mu130 standard conditions Fig. 1. with image from Snodgrass et al., 2023
blood circulation process quality, abnormal engmu130/mu130 standard conditions Fig. S4 from Sugden et al., 2017
intersegmental vein vein decreased diameter, abnormal engmu130/mu130 standard conditions Fig. 2 from Sugden et al., 2017
head vasculature eng expression decreased amount, abnormal engmu130/mu130 standard conditions Fig. S2 from Sugden et al., 2017
brain blood vessel irregular spatial pattern, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
vein endothelial cell increased amount, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
blood accumulation regenerating fin vasculature, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
heart increased size, abnormal engmu130/mu130 standard conditions Fig. 1. with image from Snodgrass et al., 2023
intersegmental vein arteriole dilated, abnormal engmu130/mu130 standard conditions Fig. 2 from Sugden et al., 2017
brain blood vessel kinked, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
regenerating fin artery increased diameter, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
posterior cardinal vein eng expression decreased amount, abnormal engmu130/mu130 standard conditions Fig. S2 from Sugden et al., 2017
regenerating fin vein increased diameter, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
intersegmental vein blood circulation decreased process quality, abnormal engmu130/mu130 standard conditions Fig. 2 from Sugden et al., 2017
regenerating fin artery increased area, abnormal engmu130/mu130 standard conditions Fig. 1 from Sugden et al., 2017
posterior cardinal vein dilated, abnormal engmu130/mu130 standard conditions Fig. 2,  Fig. S4 from Sugden et al., 2017
integument vasculature hemorrhagic, abnormal engmu130/mu130 standard conditions Fig. 1. with image from Snodgrass et al., 2023
trunk vasculature eng expression decreased amount, abnormal engmu130/+ standard conditions Fig. S2 from Sugden et al., 2017
head vasculature eng expression decreased amount, abnormal engmu130/+ standard conditions Fig. S2 from Sugden et al., 2017
posterior cardinal vein eng expression decreased amount, abnormal engmu130/+ standard conditions Fig. S2 from Sugden et al., 2017
dorsal aorta cell increased area, abnormal engmu130/mu130; mu240Tg; y7Tg standard conditions Fig. 7 from Sugden et al., 2017
dorsal aorta cell increased area, ameliorated engmu130/mu130; mu240Tg; y7Tg chemical treatment: tricaine Fig. 7 from Sugden et al., 2017
vasculature nucleate erythrocyte absent, abnormal engmu130/mu130; s843Tg; sd2Tg standard conditions Fig. 3 from Sugden et al., 2017
posterior cardinal vein YFP expression increased amount, abnormal engmu130/mu130; mu107Tg; s916Tg standard conditions Fig. 5 from Sugden et al., 2017
intersegmental vein YFP expression decreased amount, abnormal engmu130/mu130; mu107Tg; s916Tg standard conditions Fig. 5 from Sugden et al., 2017
dorsal aorta YFP expression decreased amount, abnormal engmu130/mu130; mu107Tg; s916Tg standard conditions Fig. 5 from Sugden et al., 2017
dorsal aorta dilated, ameliorated engmu130/mu130; mu156Tg standard conditions Fig. S4 from Sugden et al., 2017
posterior cardinal vein dilated, abnormal engmu130/mu130; mu156Tg standard conditions Fig. S4 from Sugden et al., 2017
blood circulation process quality, ameliorated engmu130/mu130; mu156Tg standard conditions Fig. S4 from Sugden et al., 2017
dorsal aorta diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: PD 0325901, chemical treatment by environment: sirolimus Fig. 5. with image from Snodgrass et al., 2023
basilar artery increased diameter, abnormal engmu130/mu130; s916Tg standard conditions Fig. 2. with image,  Fig. 3. with image from Snodgrass et al., 2023
dorsal aorta increased diameter, abnormal engmu130/mu130; s916Tg control Fig. 3. with image,  Fig. 4. with image,  Fig. 5. with image from Snodgrass et al., 2023
posterior cardinal vein increased diameter, abnormal engmu130/mu130; s916Tg control Fig. 3. with image,  Fig. 4. with image,  Fig. 5. with image from Snodgrass et al., 2023
brain vasculature blood vessel endothelial cell has number of blood vessel endothelial cell plasma membrane bounded cell projection, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: PD 0325901 Fig. 4. with image from Snodgrass et al., 2023
intersegmental vessel diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: tivozanib Fig. 3. with image from Snodgrass et al., 2023
optic artery increased branchiness, abnormal engmu130/mu130; s916Tg standard conditions Fig. 1. with image from Snodgrass et al., 2023
dorsal aorta diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: PD 0325901 Fig. 4. with image from Snodgrass et al., 2023
posterior cardinal vein diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: sirolimus Fig. 4. with image from Snodgrass et al., 2023
brain vasculature blood vessel endothelial cell has number of blood vessel endothelial cell plasma membrane bounded cell projection, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: PD 0325901, chemical treatment by environment: sirolimus Fig. 5. with image from Snodgrass et al., 2023
posterior cardinal vein diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: PD 0325901 Fig. 4. with image from Snodgrass et al., 2023
posterior cardinal vein diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: tivozanib Fig. 3. with image from Snodgrass et al., 2023
brain vasculature blood vessel endothelial cell has number of blood vessel endothelial cell plasma membrane bounded cell projection, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: sirolimus Fig. 4. with image from Snodgrass et al., 2023
posterior cardinal vein diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: PD 0325901, chemical treatment by environment: sirolimus Fig. 5. with image from Snodgrass et al., 2023
intersegmental vessel decreased diameter, abnormal engmu130/mu130; s916Tg control Fig. 3. with image from Snodgrass et al., 2023
dorsal aorta diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: sirolimus Fig. 4. with image from Snodgrass et al., 2023
dorsal aorta diameter, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: tivozanib Fig. 3. with image from Snodgrass et al., 2023
intersegmental vessel atretic, abnormal engmu130/mu130; s916Tg control Fig. 3. with image from Snodgrass et al., 2023
intersegmental vessel closure, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: tivozanib Fig. 3. with image from Snodgrass et al., 2023
brain vasculature blood vessel endothelial cell has number of blood vessel endothelial cell plasma membrane bounded cell projection, ameliorated engmu130/mu130; s916Tg chemical treatment by environment: tivozanib Fig. 3. with image from Snodgrass et al., 2023
brain vasculature blood vessel endothelial cell has extra parts of type blood vessel endothelial cell plasma membrane bounded cell projection, abnormal engmu130/mu130; s916Tg standard conditions Fig. 2. with image,  Fig. 3. with image,  Fig. 4. with image,  Fig. 5. with image from Snodgrass et al., 2023
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.